NEW YORK, March 15 (GenomeWeb News) - RNAi firm Atugen has raised €5 million in a third financing round, the company said today.
The financing round was managed by WestLBPanmure and co-led by new investor Novartis Venture Fund and funds advised by Apax Partners. Previous investor MPM Capital also joined the round.
Atugen, based in Berlin, Germany, is developing siRNA therapeutics.